Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Long-Term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
This study has been completed.
Sponsored by: ALTANA Pharma
Information provided by: ALTANA Pharma
ClinicalTrials.gov Identifier: NCT00261300
  Purpose

Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting reflux symptoms. One of the main symptoms of GERD is heartburn. It occurs when the acidic content from the stomach touches the lining of the esophagus, causing a burning sensation in the chest or throat. Proton pump inhibitors such as pantoprazole can relieve symptoms of GERD and peptic ulcers in a large proportion of patients.

Additionally, long-term treatment with proton pump inhibitors may be needed for patients with chronic ulcer disease not caused by H. pylori (H. pylori is a stomach-dwelling bacteria which is often associated with ulcers in the stomach or duodenum).

The aim of the study is to evaluate the long-term effect of pantoprazole in patients with chronic gastric acid-related complaints. The study duration consists of a 5-year treatment period. Pantoprazole will be administered once daily. The study will provide further data on long-term safety, tolerability, and efficacy of pantoprazole.


Condition Intervention Phase
Gastroesophageal Reflux Disease (GERD)
Peptic Ulcers
Drug: Pantoprazole
Phase III

MedlinePlus related topics: GERD Peptic Ulcer
Drug Information available for: Pantoprazole Pantoprazole Sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title: Long-Term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints

Further study details as provided by ALTANA Pharma:

Primary Outcome Measures:
  • Safety (adverse events, laboratory values). [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluation of gastrointestinal symptoms, histological parameters. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: October 2000
Study Completion Date: July 2008
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Pantoprazole 40 mg
Drug: Pantoprazole
Long term Pantoprozole trial

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Patients who completed ALTANA Pharma study BY1023/FK3006 (long-term clinical trial regarding efficacy and tolerability of Pantoprazole in patients not responding to treatment with H2-receptor antagonists or omeprazole)
  • Written informed consent

Main Exclusion Criteria:

  • Concomitant diseases
  • Pregnant or nursing female patients; female patients of childbearing potential who are not using reliable contraception
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00261300

Locations
Germany
Altana Pharma/Nycomed
Hannover, Germany, 30659
Sponsors and Collaborators
ALTANA Pharma
Investigators
Principal Investigator: Gorig Brunner, Prof. Dr. 30659 Hannover, Germany
  More Information

Responsible Party: Nycomed ( Nycomed )
Study ID Numbers: BY1023/VMG-708
Study First Received: December 2, 2005
Last Updated: January 8, 2009
ClinicalTrials.gov Identifier: NCT00261300  
Health Authority: Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)

Keywords provided by ALTANA Pharma:
Gastric acid
GERD
Gastroesophageal reflux disease
Pantoprazole
Proton pump inhibitor

Study placed in the following topic categories:
Esophageal disorder
Gastrointestinal Diseases
Ulcer
Pantoprazole
Intestinal Diseases
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Digestive System Diseases
Stomach Diseases
Esophageal Diseases
Peptic Ulcer
Duodenal Diseases

Additional relevant MeSH terms:
Therapeutic Uses
Anti-Ulcer Agents
Gastrointestinal Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009